EquityBulls

Latest News

Keywords Selected: GlenmarkPharmaceuticals

Stock Report

Glenmark Pharmaceuticals Receives U.S. FDA Approval for Progesterone Vaginal Inserts, 100 mg
Glenmark Pharmaceuticals announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS® in the U.S.
Glenmark Pharmaceuticals Launches GLIPIQ® (Semaglutide) In India
Glenmark Pharmaceuticals Inc., USA launches Authorized Generic to Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg
Glenmark Therapeutics Inc., USA launches Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
Glenmark Pharmaceuticals Inc., USA to launch Potassium Phosphates Injections
Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Competitive Generic Therapy Exclusivity
Glenmark Pharmaceuticals Inc., USA to launch Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials
Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial
Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma
Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma
Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial
Glenmark Pharmaceuticals Ltd update on USFDA PAI at Chhatrapati Sambhajinagar Facility
Glenmark Pharmaceuticals Receives Establishment Inspection Report (EIR) from U.S. FDA for its Monroe facility
Glenmark Pharmaceuticals announces Launch of Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, World's First Nebulized Triple Therapy for COPD
Cosmo and Glenmark announce Market Authorization of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 15 countries in Europe
Glenmark Pharmaceuticals Announces Q2FY26 Results
Glenmark Secures China Approval For RYALTRIS®, Reinforcing Respiratory Innovation Leadership
Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial
Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP
Glenmark Strengthens Oncology Portfolio with Hengrui's HER2 Targeting ADC For Multiple Regions
Glenmark Pharma arm receives upfront payment of $700 Mn from AbbVie
Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials
Glenmark Pharmaceuticals Inc., USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial